Life sciences practice co-head Gregory Levine (Washington, D.C.) was quoted in a December Laboratory Economics article on the uncertainty of regulating laboratory developed tests (LDTs) after the U.S. Food and Drug Administration (FDA) decided not to finalize its draft guidance issued in October 2014. The article cites a Ropes & Gray alert on LDT regulatory policy by the FDA.
Mr. Levine explains that in light of the FDA announcement, it is possible that the U.S. Congress could use the next round of Medical Device User Fee Amendments to establish a new LDT scheme if consensus can be reached.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.